Literature DB >> 7691936

Alkali hydrolysis of recombinant proteins allows for the rapid identification of class I MHC-restricted CTL epitopes.

M A Gavin1, M J Gilbert, S R Riddell, P D Greenberg, M J Bevan.   

Abstract

The characterization of the epitopes recognized by CTL provides insights into the nature of protective immune responses and facilitates the development of methods to enhance immunity to human pathogens. However, no easily applicable approach for CTL epitope identification has been developed. We present a rapid and efficient method for locating CTL epitopes within a protein. The gene encoding the protein of interest is inserted into an inducible prokaryotic expression vector. Random peptides are then generated by alkali digestion of intact or lysed Escherichia coli expressing the protein and assayed for the presence of the epitope by coating target cells for a standard CTL targeting assay. A large panel of clones containing serial 3'-deletions of the gene is then generated by exonuclease III digestion, and the expressed truncated proteins are similarly analyzed for the presence of the antigenic peptide. The epitope is located by determining the deletion points of clones expressing sequential truncations and differing in Ag expression. This technique was used to identify the H-2Ld-restricted nonamer in E. coli beta-galactosidase, with residues 876-884 representing the naturally processed epitope. To test the applicability of this method to other proteins, two genes from human CMV, an often fatal pathogen in immunocompromised individuals, were screened for HLA class I-restricted epitopes. An HLA-B18-restricted epitope from the CMV major immediate-early protein was found to lie between residues 378 and 389, and an HLA-B35-restricted epitope from the CMV pp65 matrix protein was characterized as residues 123 to 131. The results demonstrate that this technique can be used to rapidly identify CTL epitopes within a chosen protein and should be useful for assaying viral isolates or neoplasms for loss of epitopes after mutation and selection by host immune responses.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7691936

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  53 in total

1.  Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation.

Authors:  V Bronte; D B Chappell; E Apolloni; A Cabrelle; M Wang; P Hwu; N P Restifo
Journal:  J Immunol       Date:  1999-05-15       Impact factor: 5.422

2.  Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells.

Authors:  V Bronte; E Apolloni; A Cabrelle; R Ronca; P Serafini; P Zamboni; N P Restifo; P Zanovello
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

3.  Incoming human cytomegalovirus pp65 (UL83) contained in apoptotic infected fibroblasts is cross-presented to CD8(+) T cells by dendritic cells.

Authors:  G Arrode; C Boccaccio; J Lulé; S Allart; N Moinard; J P Abastado; A Alam; C Davrinche
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

4.  Sindbis viral vectors transiently deliver tumor-associated antigens to lymph nodes and elicit diversified antitumor CD8+ T-cell immunity.

Authors:  Tomer Granot; Yoshihide Yamanashi; Daniel Meruelo
Journal:  Mol Ther       Date:  2013-09-12       Impact factor: 11.454

5.  CD8(+) T-cell gamma interferon production specific for human immunodeficiency virus type 1 (HIV-1) in HIV-1-infected subjects.

Authors:  X L Huang; Z Fan; C Kalinyak; J W Mellors; C R Rinaldo
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

6.  Anthrax toxin-mediated delivery of a cytotoxic T-cell epitope in vivo.

Authors:  J D Ballard; R J Collier; M N Starnbach
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

7.  Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells.

Authors:  V Bronte; M Wang; W W Overwijk; D R Surman; F Pericle; S A Rosenberg; N P Restifo
Journal:  J Immunol       Date:  1998-11-15       Impact factor: 5.422

8.  Brain-infiltrating cytolytic T lymphocytes specific for Theiler's virus recognize H2Db molecules complexed with a viral VP2 peptide lacking a consensus anchor residue.

Authors:  N D Borson; C Paul; X Lin; W K Nevala; M A Strausbauch; M Rodriguez; P J Wettstein
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

9.  CD4-mediated and CD8-mediated cytotoxic and proliferative immune responses to Toxoplasma gondii in seropositive humans.

Authors:  M B Purner; R L Berens; P B Nash; A van Linden; E Ross; C Kruse; E C Krug; T J Curiel
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

10.  Recombinant Newcastle disease virus as a vaccine vector for cancer therapy.

Authors:  Adam Vigil; Osvaldo Martinez; Mark A Chua; Adolfo García-Sastre
Journal:  Mol Ther       Date:  2008-08-19       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.